Management of hemorrhage during gynecologic surgery

Clinical Obstetrics and Gynecology

Volumn 58, Issue 4, 2015, Pages 718-731

  Yu, Steve P ^a   Cohen, Joshua G ^a   Parker, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gynecologic hemorrhage; Gynecologic surgery; Management gynecologic hemorrhage; Management surgical hemorrhage; Postoperative hemorrhage; Surgical hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL PRODUCT; CLOPIDOGREL; FIBRIN GLUE; GELATIN MATRIX; GONADORELIN AGONIST; HEMOGLOBIN; HEMOSTATIC AGENT; HERBACEOUS AGENT; MICROCRYSTALLINE COLLAGEN; MICROPOROUS POLYSACCHARIDE SPHERE; OXIDIZED REGENERATED CELLULOSE; RECOMBINANT ERYTHROPOIETIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADVERSE DRUG REACTION; ANEMIA; ANTICOAGULANT THERAPY; AORTA BALLOON; ARTERY LIGATION; ARTICLE; ARTIFICIAL EMBOLISM; BALLOON OCCLUSION; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; BLOOD DONOR; BLOOD SALVAGE; BLOOD TRANSFUSION; BLOOD VOLUME; CAUTERIZATION; CLINICAL PROTOCOL; EPISTAXIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FAMILY HISTORY; FEMALE; GYNECOLOGIC SURGERY; HEMODILUTION; HEMOGLOBIN DETERMINATION; HERBAL MEDICINE; HUMAN; HYPOTENSION; HYSTERECTOMY; IRON THERAPY; LABORATORY TEST; MEDICAL HISTORY; MENORRHAGIA; OPERATIVE BLOOD LOSS; PATIENT CARE PLANNING; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PREOPERATIVE EVALUATION; RETROPERITONEAL HEMORRHAGE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; UTERINE ARTERY; UTERINE ARTERY LIGATION; UTERUS SURGERY; VON WILLEBRAND DISEASE; ADVERSE EFFECTS; ANAMNESIS; BLOOD LOSS, SURGICAL; HEMOSTASIS; LIGATION; MEDICATION THERAPY MANAGEMENT; PREOPERATIVE PERIOD; PROCEDURES; RISK ASSESSMENT;

ANEMIA; BALLOON OCCLUSION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; LIGATION; MEDICAL HISTORY TAKING; MEDICATION RECONCILIATION; OPERATIVE BLOOD SALVAGE; PREOPERATIVE PERIOD; RISK ASSESSMENT; UTERINE ARTERY;

EID: 84946544817     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000147     Document Type: Article

References (42)

1. Harris WJ. Early complicationsofabdominal and vaginal hysterectomy. Obstet Gynecol Surv. 1995;50:795-805.
2. Santoso JT, Saunders BA, Grosshart K. Massive blood loss and transfusion in obstetrics and gynecology. Obstet Gynecol Surv. 2005;60:827-837.
3. Carson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42:812-818.
4. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-327.
5. Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of ibuprofen. Ann Intern Med. 2005;142:506-509.
6. Kroenke K, Goobey-Toedt D, Jacksno JL. Chronic medications in the perioperative period. South Med J. 1998;91:358-364.
7. Long J. FDA GMP Inspectors Cite 70% of Dietary Supplement Firms. Available at: http://www.naturalproductsinsider.com/news/2013/05/fda-gmp-inspectors-cite-70-of-dietary-supplement. aspx. Accessed on September 9, 2013.
8. Cordier W, Steenkamp V. Herbal remedies affecting coagulation: a review. Pharm Biol. 2012;50: 443-452.
9. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286:208-216.
10. Lee A, Chui PT, Aun CS, et al. Incidence and risk of adverse perioperative events among surgical patients taking traditional Chinese herbal medicines. Anesthesiology. 2006;105:454-461.
11. Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med. 1984;144:471.
12. Werner E, Kaltwasser JP, lhm P. Oral iron treatment: intestinal absorption and the influence of a meal (author's transl). Dtsch Med Wochenschr. 1977;102:1061-1064.
13. Auerbach M, Goodnough LT, Picard D, et al. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48:988-1000.
14. de Aloysio D, Altieri P, Pretolani G, et al. The combined effect of a GnRH analog in premeno-pause plus postmenopausal estrogen deficiency for the treatment of uterine leiomyomas in peri-menopausal women. Gynecol Obstet Invest. 1995;39:115-119.
15. Segal JB, Blasco-Colmenares E, Norris EF, et al. Preoperative acute normovolemic hemodilutions: a meta-analysis. Transfusion. 2004;44:632-644.
16. Wurnig C, Schatz K, Noske H, et al. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2001;33:303-310.
17. Sesti F, Ticconi C, Bonifacio S, et al. Preoperative administration of recombinant human erythropoietin in patients undergoing gynecologic surgery. Gynecol Obstet Invest. 2002;54:1-5.
18. Gostout B, Cliby W, Podratz C. Prevention and management of acute intraoperative bleeding. Clin Obstet Gynecol. 2002;45:481-491.
19. West S, Ruiz R, Parker WH. Abdominal myo-mectomy in women with very large uterine size. Fertil Steril. 2006;85:36-39.
20. Morrow CP. Basic surgical principles. In: Paul Morrow C, ed. Morrow's Gynecologic Cancer Surgery. Encinitas: South Coast Medical Publishing; 2013:1-24. Print.
21. Tamizian O, Arulkumaran S. The surgical management of postpartum haemorrhage. Curr Opin Obstet Gynecol. 2001;13:127-131.
22. Walker Joan. Ancillary procedures. In: Karlan B, Bristow R, Li A, eds. Gynecologic Oncology: Clinical Practice and Surgical Atlas. San Francisco: McGraw Hill Medical; 2012:673-683. Print.
23. Masamoto H, Uehara H, Gibo M, et al. Elective use of aortic balloon occlusion in cesarean hysterectomy for placenta previa percreta. Gyne-col Obstet Invest. 2009;67:92-95.
24. Søvik E, Stokkeland P, Storm BS, et al. The use of aortic occlusion balloon catheter without fluo-roscopy for life-threatening post-partum haemorrhage. Acta Anaesthesiol Scand. 2012;56: 388-393.
25. Usman N, Noblet J, Low D, et al. Intra-aortic balloon occlusion without fluoroscopy for severe postpartum haemorrhage secondary to placenta percreta. Int J Obstet Anesth. 2014;23:91-93.
26. Ereth MH, Schaff M, Ericson EF, et al. Comparative safety and efficacy of topical hemostatic agents in a rat neurosurgical model. Neurosur-gery. 2008;63:369-372.
27. Borten M, Friedman EA. Translaparoscopic he-mostasis with Microfibrillar collagen in lieu of laparotomy.Areportoftwo cases. J Reprod Med. 1983;28:804-806.
28. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;48:1502-1516.
29. Lew WK, Weaver FA. Clinical use of topical thrombin as a surgical hemostat. Biologics. 2008;2:593-599.
30. Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339:245-253.
31. Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol. 2006;176: 2367-2374.
32. Anderson CK, Medlin E, Ferriss AF, et al. Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Obstet Gynecol. 2014;124:589-595.
33. Achneck HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg. 2010;251:217-228.
34. Howard R, Straughn M, Huh W, et al. Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol. 2002;100:1061-1063.
35. Balogh Z, Jones F, D'Amours S, et al. Continuous intra-abdominal pressure measurement technique. Am J Surg. 2004;188:679-684.
36. Hardy JF, Samama M. Massive transfusion and coagulopathy. Transfus Altern Transfus Med. 2003;4:199-210.
37. Erber WN. Massive blood transfusion in the elective surgery setting. Transfus Apheresis Sci. 2002;27:83-92.
38. Hiippala S. Replacement of massive blood loss. Vox Sang. 1998;74(suppl 2):399-407.
39. MacLeod JB, Winkler AM, McCoy C, et al. Early trauma induced coagulopathy (ETIC): prevalence across the injury spectrum. Injury. 2014;45: 910-915.
40. Pham HP, Shaz BH. Update on massive transfusion. Br J Anaesth. 2013;111(suppl 1): i71-i82.
41. Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma. 2009;66:41-48. Discussion 48.
42. Baraniuk S, Tilley BC, del Junco DJ, et al. Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial: design, rationale and implementation. Injury. 2014;45:1287-1295.